Dimiracetam in Painful Neuropathies Affecting AIDS Patients (DIPANAP)

Neurotune

Status and phase: Unknown; Phase 2

Conditions: Acquired Immunodeficiency Syndrome

Treatments: Drug: Dimiracetam 25 mg; Drug: Dimiracetam

Study type: Interventional

Funder types: Industry

Identifiers

NCT01444690

NT-004-DIPANAP

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and tolerability of orally administered dimiracetam for 10 weeks to AIDS patients under treatment with antiretroviral agents presenting a disease and /or treatment related neuropathic pain.

Enrollment: 244 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male and female patients aged 18-75 years inclusive;
• females of child-bearing potential only if agreeing prior to screening to use a medically accepted method of contraception, i.e., oral or injectable hormonal contraceptive with a second method of birth control, medically prescribed intrauterine device (IUD), or double barrier method (condom in combination with spermicidal). Females, who are not currently sexually active, only if agreeing and consenting to use one of the above-mentioned methods in case they become sexually active while participating in the study;
• females of not child-bearing potential only if permanently sterilised or if in post-menopausal status, only if they have been in this status for at least 2 years; females of not child-bearing potential are exempted from the requirement for use of contraception;
• HIV-positive patients treated with ARTs;
• CD4+ cell count > 200/μL at the screening;
• patients affected by current neuropathic pain likely to be ART treatment related. The diagnosis shall be made by a physician and based on history, clinical and/or laboratory findings in accordance with the taxonomy of the diagnostic criteria documented in the International Association for the Study of Pain (IASP) Classification of Chronic Pain;
• naïve neuropathic patients or non-responders (residual pain ≥40 mm on the VAS) to standard neuropathy treatments. Drugs for neuropathic pain (NP) must be stopped at screening visit;
• pain intensity ≥40 mm on the VAS at screening;
• pain intensity ≥40 mm on the VAS as the mean of the values collected on the last 4 days prior to the start of treatment (baseline VAS);
• life expectancy of at least 6 months;
• ability to comprehend the full nature and purpose of the study, including possible risks and side effects;
• ability to co-operate with the Investigator or designee and to comply with the requirements of the entire study

Exclusion criteria

• pregnant or lactating females;
• presence of active AIDS-defining opportunistic infections (with the exception of tuberculosis) or malignant neoplasia requiring treatment at study entry or Kaposi's sarcoma or another malignant neoplasia likely to require chemotherapy;
• any clinically significant underlying disease, according to the Investigator's clinical judgment;
• history of psychosis (e.g. schizophrenia or psychotic depression) or major depression (requiring treatment);
• any current DSM-IV Axis I diagnosis including dementia, depression, psychosis, anxiety disorders, mental retardation;
• participation in the evaluation of any investigational drug within 3 months prior to screening (6 months if for treatment of neuropathic pain)
• treatment with neurostimulating devices such as spinal cord stimulation (SCS), acupuncture, homeopathic remedies for pain or any kind of surgical treatment or blockade for the pain in the 4 weeks prior to screening;
• treatment with any drug for neuropathic pain (NP) after the screening visit;
• requirement of more than 2 transfusions / month to achieve haemoglobin level > 8 g/dL;
• history of alcohol abuse (no more than 4 drinks in a day and 14 drinks in a week for men or 3 drinks per day and 7 drinks in a week for women as defined according to both NIAAA and USDA dietary guidelines) or drug abuse during the last 3 mo prior to screening;
• Less than 1 VAS assessment per day for each of the last 4 days.
• history of allergic response to neuropathic treatments or history of anaphylaxis or allergic reactions to drugs in general;
• any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in diagnostic laboratory test;
• subjects likely to be non-compliant or uncooperative during the study according to the Investigator or designee's judgement

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

244 participants in 2 patient groups, including a placebo group

Active

Experimental group

Description:

Dimiracetam 400 mg capsules

Treatment:

Drug: Dimiracetam

Pseudo-placebo

Placebo Comparator group

Description:

Dimiracetam 25 mg capsules

Treatment:

Drug: Dimiracetam 25 mg